Novel Arylazoarylmethane as Potential Inhibitor of Macrophage Migration Inhibitory Factor

Publication Date

2014

Journal Title

Archiv Der Pharmazie

Abstract

Macrophage migration inhibitory factor (MIF), a cytokine involved in the pathogenesis of sepsis, diabetes, asthma, arthritis, and cancer, has an enzymatic active site that has proven to be an effective target for small molecule-based inhibitors. Herein, we describe the synthesis of a novel arylazoaryl-methane compound (3) from a known arylhydrazone MIF inhibitor (2). This new compound has improved stability and in vivo biological activity.

Volume Number

347

Issue Number

2

Pages

104-107

Document Type

Article

Status

Faculty, Northwell Researcher

Facility

School of Medicine; Northwell Health

Primary Department

Molecular Medicine

Additional Departments

General Internal Medicine; Obstetrics and Gynecology

PMID

24243226

DOI

10.1002/ardp.201300243

For the public and Northwell Health campuses

Share

COinS